Loading...
XKRX
229000
Market cap16mUSD
May 02, Last price  
1,737.00KRW
1D
-1.42%
1Q
-7.31%
IPO
-89.04%
Name

Gencurix Inc

Chart & Performance

D1W1MN
P/E
—
P/S
4.49
EPS
—
Div Yield, %
—
Shrs. gr., 5y
19.96%
Rev. gr., 5y
106.53%
Revenues
5.13b
+97.43%
577,789,630585,810,4476,731,063252,320,050136,618,4941,571,991,6173,046,945,8862,559,487,1842,600,317,6605,133,768,890
Net income
-4.15b
L-78.46%
-3,981,919,817-9,063,948,157-6,819,877,293-5,724,463,484-9,162,256,48533,108,403,240-34,670,022,631-24,596,962,223-19,260,021,040-4,147,842,270
CFO
-7.17b
L-34.07%
-2,269,091,712-5,981,751,933-5,408,516,102-5,033,560,206-5,222,008,254-13,587,563,335-8,366,162,665-10,452,261,269-10,876,925,490-7,170,928,310
Earnings
May 12, 2025

Profile

Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a device for loop-mediated isothermal amplification. The company was founded in 2011 and is headquartered in Seoul, South Korea.
URL
http://www.gencurix.com/
IPO date
Oct 27, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,133,769
97.43%
2,600,318
1.60%
2,559,487
-16.00%
Cost of revenue
8,665,032
8,540,396
8,259,119
Unusual Expense (Income)
NOPBT
(3,531,264)
(5,940,079)
(5,699,632)
NOPBT Margin
Operating Taxes
10,550
(155,315)
(650)
Tax Rate
NOPAT
(3,541,813)
(5,784,763)
(5,698,982)
Net income
(4,147,842)
-78.46%
(19,260,021)
-21.70%
(24,596,962)
-29.05%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,937,317
25,001,821
BB yield
-23.39%
-34.00%
Debt
Debt current
9,208,491
12,219,659
4,236,237
Long-term debt
1,705,669
4,879,163
3,999,030
Deferred revenue
Other long-term liabilities
160,572
1,142,900
1,847,638
Net debt
6,748,715
641,605
(12,314,896)
Cash flow
Cash from operating activities
(7,170,928)
(10,876,925)
(10,452,261)
CAPEX
(664,572)
(2,176,977)
(13,046,042)
Cash from investing activities
5,727,178
(6,717,682)
(3,174,872)
Cash from financing activities
(732,554)
14,650,596
7,481,056
FCF
(3,357,259)
(19,323,812)
(4,316,656)
Balance
Cash
4,539,945
11,269,693
5,858,157
Long term investments
(374,499)
5,187,524
14,692,005
Excess cash
3,908,757
16,327,201
20,422,188
Stockholders' equity
(80,939,561)
(80,182,479)
(61,918,161)
Invested Capital
106,564,106
110,236,523
77,525,242
ROIC
ROCE
EV
Common stock shares outstanding
15,057
11,821
7,430
Price
1,970.00
-68.33%
6,220.00
-10.12%
6,920.00
-61.34%
Market cap
29,661,939
-59.66%
73,529,008
43.01%
51,415,593
-60.76%
EV
36,410,654
72,421,552
38,458,134
EBITDA
(2,055,099)
(4,549,485)
(4,784,514)
EV/EBITDA
Interest
767,024
810,725
478,246
Interest/NOPBT